NCT07046741已完成不适用
Etat de Lieux de l'Allaitement Maternel Exclusif et Facteurs Prédictifs au CH de Martigues
Centre Hospitalier de Martigues1 个研究点 分布在 1 个国家目标入组 309 人开始时间: 2024年8月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 309
- 试验地点
- 1
- 主要终点
- Rate of maternal breastfeeding at three month (M3)
研究概览
简要总结
Evaluate the prevalence of exclusive breastfeeding at M3 within the Martigues CH.
详细描述
After delivery, the investigating midwife or investigating pediatrician can go to the room where the new mother is installed to present the study to her. Once the patient consents, an information note will be given to her after signing a non-opposition.
The investigator or designated caregiver will produce the hetero-questionnaire in paper form to be completed depending on the patient's availability.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Woman aged 18 and over
- •Having given birth to a healthy child (or multiples) regardless of the number of weeks of amenorrhea
- •Women practicing exclusive breastfeeding from the birth of the newborn
- •Able to speak, read and understand French
- •Having given oral consent
排除标准
- •Minor mothers
- •Refusal of consent
- •Mothers wishing to practice artificial breastfeeding upon leaving the maternity ward will be excluded in M1 and M3
- •Women who have changed their mind about exclusive breastfeeding during their maternity stay will be excluded
结局指标
主要结局
Rate of maternal breastfeeding at three month (M3)
时间窗: up of 3 month
Proportion of mothers that continue exclusive breastfeeding at 3 months at Martigues Hospital
次要结局
- Rate of exclusive breastfeeding at 1 month (M1)(1 month)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
Unknown
The barriers to Exclusive Breast Feeding for mothers.CTRI/2024/07/070490Helena Maria Prasad
进行中（未招募）
1 期
The study to assess the efficacy and safety of new Interferon alpha-2b formulation in patients with primary myelofibrosisPrimary Myelofibrosis (grade MF-0 and MF-1) according to the WHO criteriaMedDRA version: 17.0 Level: LLT Classification code 10053134 Term: Osteomyelofibrosis System Organ Class: 100000004864EUCTR2014-001367-13-ATMedizinische Universtät Wien, Universitätsklinik für Innere Medizin I24
终止
1 期
A Phase 1b, Multicentre, Open Label, Study of the Efficacy, Safety and Tolerability of R131 Ointment in Women with Cytological Abnormalities of the Uterine Cervixcervical intraepithelial neoplasia caused by Human papilloma virusCancer - Cervical (cervix)Reproductive Health and Childbirth - Other reproductive health and childbirth disordersACTRN12618001726246Douglas Pharmaceuticals Ltd13
进行中（未招募）
1 期
Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple MyelomaHigh-risk smoldering multiple myelomaCTIS2023-510560-12-00Fundacion Pethema20
已完成
1 期
Phase 1 Trial of MK-4830 as Monotherapy and Combination with PembrolizumabAdvanced solid tumorJPRN-jRCT2031210025Hoki Toshifumi3